科克伦的研究发现抗粉样性阿尔茨海默病药物没有显著临床效益. Cochrane review finds anti-amyloid Alzheimer's drugs offer no meaningful clinical benefit.

一项针对20,000多名患者的新科克伦综述发现,像莱卡尼马布和唐纳玛布这样的抗粉样类阿尔茨海默病药物没有显著的临床益处,对认知的影响被描述为微不足道. A new Cochrane review of over 20,000 patients finds that anti-amyloid Alzheimer’s drugs like lecanemab and donanemab provide no meaningful clinical benefit, with effects on cognition described as trivial. 虽然这些药物减少脑斑, 但它们有胀和出血的风险, 并给患者带来很大的负担. While these drugs reduce brain plaque, they carry risks of swelling and bleeding and impose a heavy burden on patients. 批评者认为,该审查不公平地将新药与失败的试验组合在一起, 这表明这些药物确实对一些早期患者提供了适度的益处. Critics argue the review unfairly groups failed trials with newer ones, suggesting the drugs do offer modest benefits for some early-stage patients.